Q4 2024 Aurinia Pharmaceuticals Inc Earnings Call Transcript
Key Points
- Aurinia Pharmaceuticals Inc (AUPH) reported a significant growth in total revenue, with a 33% increase in the fourth quarter of 2024 compared to the same period in 2023.
- Net product sales of LUPKYNIS increased by 36% in both the fourth quarter and full year of 2024, driven by further market penetration.
- The company generated positive cash flow from operations, improving from a cash flow deficit in 2023 to a positive cash flow of $44.4 million in 2024.
- Aurinia Pharmaceuticals Inc (AUPH) has a strong cash position with cash equivalents, restricted cash, and investments totaling $358.5 million as of December 31, 2024.
- The company is advancing its pipeline with the development of AUR200, a potentially best-in-class dual BAFF and APRIL inhibitor, with initial results expected in the second quarter of 2025.
- The cost of revenue increased significantly for the full year 2024, primarily due to the amortization of the finance rate of use lease asset.
- Gross margin decreased from 92% in 2023 to 88% in 2024, indicating a slight decline in profitability.
- Total operating expenses, although reduced, still amounted to $239.8 million for the year, reflecting ongoing high costs.
- The company ceased development of its AUR300 program, which may impact future growth opportunities.
- Aurinia Pharmaceuticals Inc (AUPH) faces potential competition and patent challenges, with generic filings expected, which could impact future market exclusivity for LUPKYNIS.
Greetings and welcome to the Aurinia Pharmaceuticals fourth quarter and full year 2024 earnings call.
(Operator Instructions)
I would now like to turn the conference over to your host, Andrea Christopher, Head of Corporate Communication and Investor Relations for Aurinia. Thank you. You may begin.
Thank you, operator, and thank you to everyone for joining today's call and webcast. Joining me on the call this morning are Peter Greenleaf, Aurinia's President and Chief Executive Officer, Joe Miller, Aurinia's Chief Financial Officer, and Dr. Greg Keenan, Aurinia's Chief Medical Officer.
Today we will review and discuss Aurinia's fourth quarter and full year 2024 financial results and provide an update on recent corporate progress, as communicated in the company's press release and annual report on Form 10k issued this morning.
For more information, please refer to Aurinia's filings with the US Securities and
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
